NCT05750290招募中2 期
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Best objective response rate
研究概览
简要总结
CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Failed 2 or more lines of chemotherapy
- •Tumor overexpressing either MET or EGFR
- •Measurable lesion
排除标准
- •Prior treatment with anti-MET/EGFR bispecific antibody
研究组 & 干预措施
CKD-702 in combination with irinotecan
Experimental
干预措施: CKD-702 in combination with irinotecan (Drug)
结局指标
主要结局
Best objective response rate
时间窗: Through study completion, an average of 24 weeks
RECIST v1.1
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC PatientsMetastatic Colorectal CancerNCT06403709Cancer Institute and Hospital, Chinese Academy of Medical Sciences35
已完成
1 期
Dose-Finding Study of E7070 in Combination With IrinotecanCancerNCT00060567Eisai Inc.88
已完成
1 期
ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal CancerColorectal CarcinomaColorectal TumorsColorectal NeoplasmsNCT01675128National Cancer Institute (NCI)24
Unknown
1 期
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard TherapyNon-Small Cell Lung CancerNCT04667975Chong Kun Dang Pharmaceutical74
撤回
1 期
KRN7000 in Treating Patients With Solid TumorsUnspecified Adult Solid Tumor, Protocol SpecificLung CancerNCT00003985European Organisation for Research and Treatment of Cancer - EORTC